摘要:目的：探讨成都地区体检人群中丙氨酸氨基转移酶（ALT）升高率与其升高的相关因素,为正确分析引起ALT升高的原因提供相关依据。方法:以参与体检的8734名体检人群为研究对象,收集身高、体重、血压、丙氨酸氨基转移酶、空腹血糖、高密度脂蛋白、低密度脂蛋白、总胆固醇、甘油三酯、血清HBsAg、脂肪肝及胆石症等相关资料进行分析。结果:在全部体检人群中,ALT升高率为1011%,男性ALT升高率为13.70%,女性ALT升高率为6.30%,男性明显高于女性（Plt;0001）；ALT升高组的年龄均数小于ALT正常组（Plt;0001）；在ALT升高的受检者中,脂肪肝、高脂血症、肥胖、糖尿病、胆囊结石、饮酒及乙肝等患病率均高于ALT正常组受检者（Plt;005）。结论:脂肪肝、糖脂代谢紊乱及乙肝是体检人员ALT升高的主要原因；男性和低龄也是体检者ALT升高的危险因素。Abstract: Objective: To investigate the prevalence and relative factors of elevated serum alanine aminotransferase(ALT) levels and providescientific bases for its causes analysis in physical examination people in Chengdu. Methods: Subjects who received medical examination in physical examination center of west China hospital were screened in this study. The information of height, body weight, blood pressure, serum ALT, fasting plasma glucose, highdensity lipoprotein cholesterol, lowdensity lipoprotein cholesterol, total cholesterol, triglyceride, hepatitis B surface antigen (HBsAg) statue, fatty liver and cholelithiasis were collected and analyzed. 〖WT5”HZ〗Results:〖WT5”BZ〗 A total of 8734 cases were included in this study. The total prevalence of elevated ALT was observed in 1011%, including 137% in man and 63% in woman, and this difference between man and woman was statistic significant (P＜0001). The mean age of ALT elevated group was obvious lower than that of normal ALT group (P＜0001). Interesting, the occurrence rates of fatty liver, hyperlipidemia, obesity, diabetes,gallstones, drinking and positive hepatitis B surface antigen in ALT elevated group were all significant higher than that in normal ALT group (P＜005). Conclusion: Fatty liver, glyeolipid metabolism disorder, and hepatitis B were main reasons of elevated ALT. Male and young cases were both high risk of elevated ALT in this study.
目的：对原发性脂肪肝（PFLD）患者及健康对照的一级亲属中PFLD发生情况、胰岛素抵抗（HOMA-IR）指数以及其他相关代谢指标的测定，了解PFLD是否有家族集聚现象及IR在其发病中的可能作用。方法：PFLD的诊断依据B超为脂肪肝并排除继发性原因。PFLD家系组（A组）共42例，11个家庭。选取与A组年龄、性别构成及生活方式和经济状况相近的健康志愿者家系为对照组（B组）共14例，4个家庭。所有受试者均进行身高、体重、腰围、血压等测定，行糖耐量试验、胰岛素及血脂质等检测，并对受试者的生活方式及文化程度和经济状况行量化打分。结果：A组PFLD 33例（78.57%，A1组），无脂肪肝9例（A2组），说明有家族集聚现象。与B组相比，A1组的体重指数、腰围、舒张压、血总胆固醇和HOMA-IR指数显著高于B组（P＜0.05）；血高密度脂蛋白胆固醇（HDL-C）显著低于B（P＜0.05）；A2组的各项指标与B组相比差异无统计学意义，但变化趋势呈现出腹型肥胖、IR、代谢紊乱和血压偏高；而A1组及A2组与B组的生活方式及经济状况无明显差异。结论：PFLD具有较强的家族聚发现象，其IR程度显著高于对照组；家族中无脂肪肝者存在IR相关的代谢紊乱趋势。说明某种内在或遗传因素如IR可能与PFLD发病有关。
ObjectiveTo investigate the feasibility of proton magnetic resonance spectroscopy (1H-MRS) imaging, by which to quantitatively analyze liver fat content for therapeutic evaluation of fatty liver at 3.0 T MRI. MethodsTwenty-six patients who diagnosed with fatty liver were examined with proton MRS at Siemens Trio Tim 3.0 T MRI before treatment and 3, 6 months after treatment, respectively. The water peak, fat peak, water peak area, and fat peak area were detected, and the relative lipid content 1 (RLC1) and relative lipid content 2 (RLC2)were calculated. Fatty liver index (FLI) was referred to the standard which was calculated from triglycerides (TG), gammaglutamyl-transferase (GGT), waist circumference, and body mass index. ResultsThere were significantly different differences of RLC1 and RLC2 among before treatment and 3, 6 months after treatment (Plt;0.05). Compared with before treatment, the RLC1 and RLC2 values significantly decreased on month 3 or 6 after treatment (Plt;0.05). There were positive correlation between RLC1 or RLC2 and FLI (r=0.476, Plt;0.00; r=0.475, Plt;0.001). The intraclass correlation coefficient was more than 0.75 before treatment, the repeatability was better. ConclusionsProton MRS can quantitatively measure liver fat content. It can be reliably used for dynamic monitoring the therapeutic effects for fatty liver. Proton MRS is accurate, and has a good clinical application in dynamically monitoring the progression of fatty liver and evaluating the therapeutic effects of various treatments.
Objective To investigate the diagnostic value of proton magnetic resonance spectroscopy （1 H-MRS） on the quantification of hepatic steatosis at 3.0 T MR united.Methods Twenty-two patients who were candidated for liver surgery (living liver transplantation donor candidates, lobectomy or segmental resection for focal liver diseases, etc.) were enrolled in this study. 1 H-MRS was conducted with point resolved selective spectroscopy （PRESS） sequence, using SAGE software packages. The values of water peak (PW), lipid peak (PL) were measured, the area under water peak (AW) and lipid peak (AL), and then the relative lipid content of liver cells (RLC1, RLC2) was calculated. All subjects underwent surgical resection of liver shortly after MR scanning, fresh frozen specimens were obtained for Sudan Ⅲ staining, and staging was conducted.Results In all 22 patients, 7 patients without fatty liver, 11 patients with mild fatty liver, 4 patients with moderate or severe fatty liver. Intercomparison between different histopathological grades showed following findings: the values of PL, AL, RLC1 and RLC2 had statistical significance (Plt;0.05). The values of PL， AL， RLC1 and RLC2 were positively correlated with the proportion of fatty degenerative cells (PFDC), Plt;0.05, and the highest correlation factor was 0.771 (RLC1 to the PFDC).Conclusion 1 H-MRS can accurately quantify liver fat content and reflect the severity of hepatic steatosis. It has the potential to replace invasive liver biopsy.
Objective To evaluate the value of medical imaging technology in qualitative and quantitative diagnosis of liver steatosis. Methods To describe the current status and advancement s of medical imaging technology such as sonography , CT and MRI in qualitative and quantitative diagnosis of liver steatosis , and to cont rast their advantages and shortages. Results Sonography could be used as the primary screening and evaluate measures in qualitative and quantitative diagnosis of liver steatosis , and CT was more reliable in quantitative diagnosis , MRI had significant improving with its high sensitivity and specificity. Conclusion Medical imaging technology has significant clinical value in qualitative and quantitative diagnosis of liver steatosis , especially with the help of functional MR imaging techniques such as spect roscopy and chemical shif t Gradient-Echo technic.
Objective To explore the relationship between different diagnostic criteria (ATPIII2002, IDF2005 and CDS2007 criteria) for metabolic syndrome (MS) and non-alcoholic fatty liver disease (NAFLD). Methods A total of 666 elderly males admitted to West China Hospital for routine physical examination were involved in this study in May, 2010. The diagnostic agreement rates of different criteria were compared, along with the relationship between different diagnostic criteria for MS and NALFD. Results The diagnostic agreement of CDS2007 criteria with either IDF2005 or ATPIII2002 criteria was good. However, the agreement of ATPIII2002 with IDF2005 was compromised. The prevalence of NAFLD in MS group was significantly higher than that of non-MS group (Plt;0.01). On the basis of CDS2007 criteria, there was significant correlation between NAFLD and MS (Plt;0.000). Conclusion There is a close relation between NAFLD and all three diagnostic criteria of MS. NAFLD is one of the most important risk factors of MS. The diagnostic agreement of CDS2007 criteria with the other two is good, and there is significant correlation between NAFLD and criteria CDS2007 of MS. CDS2007 is found to be of high accuracy and applicability in the diagnosis of MS in Chinese population including the elderly.
目的 了解成都地区非酒精性脂肪肝（NAFLD）及高尿酸血症（HUA）患病情况及相关因素。 方法 对2010年9月－2011年3月健康体检的36 000名18岁以上受检者，进行病史采集、体格检查、空腹血糖、血脂、肝功能、肾功能、血尿酸检测以及上腹部彩色多普勒超声检查。 结果 高尿酸血症（HUA）的总患病率为18.17%。NAFLD患者HUA患病率为39.41%，明显高于总患病率（P＜0.01）。NAFLD患者的HUA患病率随体质量指数（BMI）的增加呈递增趋势。BMI、舒张压、甘油三酯、胆固醇、丙氨酸转氨酶、门冬氨酸氨转移酶、谷氨酰转肽酶、血肌酐、胱抑素C均随着血尿酸水平的升高而递增；高密度脂蛋白随着血尿酸水平的升高而递减。 结论 NAFLD及HUA关系密切，且二者与代谢紊乱联系紧密。
目的 观察罗格列酮钠对血糖控制未达标的2型糖尿病（T2DM）合并与不合并非酒精性脂肪肝（NAFL）患者的降糖疗效和安全性。 方法 2009年1月－2011年1月60例仅用磺脲类和二甲双胍治疗血糖控制未达标的T2DM患者，按合并和不合并NAFL分为观察组和对照组各30例，两组均在原口服降糖药基础上联合加用国产罗格列酮钠4 mg 1次/d，治疗共3个月，观察治疗前后的血糖、胰岛素、糖化血红蛋白（HbA1c）、体质量指数（BMI）、血脂、肝功、血压水平以及药物不良反应，并比较治疗后的血糖达标率。 结果 两组患者治疗后的空腹血糖（FPG）、餐后2 h血糖（2hPG）、HbA1c、空腹胰岛素、甘油三酯和极低密度脂蛋白胆固醇均较治疗前下降，高密度脂蛋白胆固醇较治疗前升高（P＜0.05），而丙氨酸转氨酶、总胆固醇、低密度脂蛋白胆固醇及血压无明显变化（P＞0.05），但观察组治疗后的FPG和2hPG均较对照组下降更明显（P＜0.01），且血糖达标率为73.3%，显著高于对照组的46.7%（P＜0.05），同时观察组餐后2 h胰岛素（2hINS）水平在治疗前后均明显高于对照组而且治疗后有显著下降（P＜0.01），但对照组治疗后2hINS虽然也有下降但无统计学意义（P＞0.05）。观察组治疗前后BMI无明显变化，但对照组治疗后BMI有明显的升高（P＜0.05）。结论 国产罗格列酮钠片对血糖控制未达标的T2DM合并和不合并NAFL患者均有进一步降低血糖、HbA1c以及改善血脂的作用，但对T2DM合并NAFL的患者的降糖疗效更显著，未见加重肝功能损坏，不良反应小，可作为此类患者联合用药的一种选择。